Extended ECG Monitoring in HCM Patients — EXAMINE-HCM  

Atrial Fibrillation Clinical Trial

Official title: Extended Ambulatory Monitoring With iRhythm Zio XT Improves Care of Patients With Hypertrophic Cardiomyopathy

Status Completed

Clinical Trial Summary

The purpose of this study is to determine, among a large cohort of 300 consecutive patients with hypertrophic cardiomyopathy, if extended ambulatory monitoring using the iRhythm Technologies, Inc. Zio XT device results in identifying a greater burden of nonsustained ventricular tachyarrhythmia (nsVT) compared to current ACCF/AHA guideline recommended 48-hour monitoring.

Clinical Trial Description

Optimal duration to monitor patients for identifying nsVT remains unclear. The investigators aim to determine the prevalence and burden of nsVT with longer term monitoring with the iRhythm Zio XT device over a 2-week period vs. 48 hours; and whether, this greater burden of nsVT compared to conventional shorter monitoring potentially identifies a subset of HCM patients who may be at higher risk of sudden cardiac death. ;

Related Conditions & MeSH terms

• Arrhythmia
• Atrial Fibrillation
• Cardiomyopathies
• Cardiomyopathy, Hypertrophic
• Hypertrophic Cardiomyopathy
• Hypertrophy
• Nonsustained Ventricular Tachycardia
• Tachycardia
• Tachycardia, Ventricular
• Ventricular Tachycardia

• NCT number: NCT04056715
• Study type: Observational
• Source: iRhythm Technologies, Inc.
• Status: Completed
• Start date: January 14, 2020
• Completion date: April 18, 2022